Hofvind Solveig, Wang Hege, Thoresen Steinar
Cancer Registry of Norway, Oslo, Norway.
Acta Oncol. 2004;43(5):467-73. doi: 10.1080/02841860410034315.
Continuous emphases of quality control are required to achieve reduction in mortality from breast cancer as a consequence of breast cancer screening. Results of the process indicators in the first 6 years in 4 counties in the Norwegian Breast Cancer Screening Program are evaluated and will be presented. Data from women who had their initial (n = 173402) and subsequent (n = 220 058) screening provide the basis for the analysis. The breast cancer detection ratio was 3.2 the expected incidence (based on the incidence before the screening started, 1991-1995) among the initially screened women, decreasing to 2.3 among the subsequently screened. The ratio of interval cancer among the initially screened was 0.25 and 0.72 of the expected incidence, 0-12 and 13-23 months after screening, respectively. For those subsequently screened the proportions were 0.22 and 0.64, respectively. More than 50% of the invasive tumors were less than 15 mm in size, and more than 75% were lymph node negative, among both the initially and subsequently screened. The process indicators achieved in the NBCSP are promising as regards future mortality reduction. The incidence of interval cancer 13-24 months after screening is higher than recommended in the European guidelines.
要通过乳腺癌筛查降低乳腺癌死亡率,就需要持续强调质量控制。对挪威乳腺癌筛查项目中4个县前6年的过程指标结果进行了评估并将予以呈现。来自接受首次筛查(n = 173402)和后续筛查(n = 220058)女性的数据为分析提供了基础。在首次接受筛查的女性中,乳腺癌检出率为预期发病率(基于1991 - 1995年筛查开始前的发病率)的3.2倍,在后续接受筛查的女性中降至2.3倍。首次接受筛查的女性中,筛查后0 - 12个月和13 - 23个月时,间期癌的比例分别为预期发病率的0.25和0.72。对于后续接受筛查的女性,这两个比例分别为0.22和0.64。在首次和后续接受筛查的女性中,超过50%的浸润性肿瘤大小小于15mm,超过75%为淋巴结阴性。挪威乳腺癌筛查项目所取得的过程指标对于未来降低死亡率很有前景。筛查后13 - 24个月的间期癌发病率高于欧洲指南中的推荐值。